Metsera said it expects the Pfizer deal to close promptly after a stockholder meeting scheduled for this coming Thursday ...

The Centers for Medicare & Medicaid Services (CMS) is calling its pilot scheme the GENErating cost Reductions fOr US Medicaid or GENEROUS model, and is now seeking companies that wish to take part.

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...

Eisai has already reached settlement agreements with two other companies seeking to market Lenvima generics in the US – Sun ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

The DESTINY-Breast11 trial showed in patients with high-risk HER2-positive early breast cancer that the ADC followed by ...

The second batch of Commissioner's national priority vouchers (CNPVs) has been published by the FDA, and includes new GLP-1 ...

That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...

The new data from the OASIS 4 trial of Novo Nordisk's 25 mg oral formulation of semaglutide included an indirect comparison ...